Mechanisms of drug resistance in cancer cells

Pakistan Journal of Medical Sciences

Volumn 19, Issue 2, 2003, Pages 118-127

  Iqbal, Mohammad Perwaiz ^a  

^a AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

Cancer cells; Drug resistance; Mechanism; Methotrexate

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; CELL PROTEIN; CYTOCHROME P450; GLUTATHIONE; GLYCOPROTEIN P; METHIONINE ADENOSYLTRANSFERASE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; POLYGLUTAMIC ACID; PROTEIN BCL XL; PROTEIN P53; RETINOBLASTOMA PROTEIN; SODIUM CHANNEL PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; DRUG TRANSPORT; GENE AMPLIFICATION; GENE MUTATION; HUMAN; MAMMAL CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0038799815     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Osborn MJ, Freeman M & Huennekens FM. Inhibition of dihydrofolic reductase by aminopterin and amethopterin. Proc Soc Exp Biol Med 1958;97:429.
2. Dunlap RB, Harding NG & Huennekens FM. Thymidylate synthetase and its relationship to dihydrofolate reductase. Ann NY Acad Sci 1971;186:153-165.
3. Jolivet J, Cowan KH, Curt CA, Clendeninn NJ & Chabner BA. The pharmacology and clinical use of methotrexate. New Engl J Med 1983;309:1094-1194.
4. Williams FM & Flintoff WF. Isolation of a human cDNA that complements a mutant hamster cell defective in methotrexate uptake. J Biol Chem 1995;270:2987-92.
5. Moscow JA, Gong M, He R, Sgagias MK, Dixon KH, Anzick SL et al. Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res 1995;55:3790-4.
6. Wong SC, Proefke SA, Bhushan A & Matherly LH. Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells. J Biol Chem 1995;270:17468-75.
7. Kuehl M, Brixner DI, Broom AD, Avery TL & Blakley RL. Cytotoxicity, uptake, polyglutamate formation and antileukemic effects of 8-deaza analogues of methotrexate and aminopterin in mice. Cancer Res 1988;48:1481-1488.
8. Cowan KH & Jolivet J. A noval mechanism of resistance to methotrexate in human breast cancer cells: lack of methotrexate polyglutamate formation. Clin Res 1983;31:508a.
9. Pizzorno G, Mini E, Coronnello M, McGuire JJ, Moroson BA, Cashmore AR et al. Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high dose treatment with this drug. Cancer Res 1988;48:2149-55.
10. Li WW, Waltham M, Tong W, Schweitzer BI & Bertino JR. Increased activity of gamma-glutamyl hydrolase in human sarcoma cell lines: a novel mechanism of intrinsic resistance to methotrexate. In: Ayling JE, Nair MG, Baugh CM, eds. Chemistry and biology of pteridines and folates. Vol 338 of Advances in Experimental Medicine and Biology, New York, Plenum Press, 1993;338:635-8.
11. Rhee MS, Wang Y, Nair MG & Galivan J. Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity. Cancer Res 1993;53:2227-30.
12. Barrueco JR, O'Leary DF & Sirotnak FM. Metabolic turnover of methotrexate polyglutamates in lysosomes derived from S180 cells. Definition of a two-step process limited by mediated lysosomal permeation of polyglutamates and activating reduced sulfhydryl compounds. J Biol Chem 1992;267:15356-61.
13. Ling V, Gerlach J & Kartner N. Multidrug resistance. Breast Cancer Res Treat 1984;4:89-94.
14. Gerlach JH, Kartner N, Bell DR & Ling V. Multidrug resistance. Cancer Surv 1986;5:25-46.
15. Riordan JR, Deuchars K, Kartner N, Alon N, Trent J & Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 1985;316:817-9.
16. Keizer HG, Schuurhuis GJ, Broxterman HJ, Lankelma J, Schoonen WG, Van Rijn J et al. Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells. Cancer Res 1989;49:2988-93.
17. Bell DR, Gerlach JH, Kartner N, Buick RN & Ling V. Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J Clin Oncol 1985;3:311-5.
18. Klohs WD, Steinkampf RW, Besserer JA & Fry DW Cross resistance of pleiotropically drug resistant P338 leukemia cells to the lipophilic antifolates trimetrexate and BW 301U. Cancer Lett 1986;31:253-60.
19. Nooter K, Bosman FT, Burger H, Van-Wingerden KE, Flens MJ, Scheper RJ et al. Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer. Ann Oncol 1996;7:75-81.
20. Aszalos A, Thompson K, Yin JJ & Ross DD. Combinations of P-glycoprotein blockers, verapamil, PSC833 and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp). Anticancer Res 1999;19:1053-64.
21. Schimke RT, Kaufman RJ, Alt FW & Kellems RF. Gene amplification and drug resistance in cultured murine cells. Science 1978;202:1051-5.
22. Schimke RT. Gene amplification and drug resistance. Sci Am 1980;243:60-9.
23. Barsoum J, Levinger L & Varshavsky A. On the chromatin structure of the amplified, transcriptionally active gene for dihydrofolate reductase in mouse cells. J Biol Chem 1982;257:5274-82.
24. Bostock C. & Clark EM. Gene amplification in methotrexate-resistant mouse cells. V. Intact amplified units can be transferred to and amplified in methotrexate sensitive mouse L cells. Chromosoma 1983;88:31-41.
25. Brown PC, Tlsty TD & Schimke, RT. Enhancement of methotrexate resistance and dihydrofolate reductase gene amplification by treatment mouse 3T6 cells with hydroxyurea. Mol Cell Biol 1983;3:1097-107.
26. Cowan KH, Goldsmith ME, Levine RM, Aitken SC, Douglass E, Clendeninn N et al. Dihydrofolate reductase gene amplification and possible rearrangement in estrogen-responsive methotrexate-resistant human breast cancer cells. J Biol Chem 1982;257:15079-15086.
27. Crouse GF, Simonsen CC, McEwan RM & Schimke RT. Structure of amplified normal and variant dihydrofolate reductase genes in mouse sarcoma S180 cells. J Biol Chem 1982;257:7887-7897.
28. Domin BA, Grill SP & Cheng Y. Establishment of dihydrofolate reductase-increased human cell lines and relationship between dihydrofolate reductase levels and gene copy. Cancer Res 1983;43:2155-2158.
29. Flintoff WF, Weber MK, Nagainis CR, Essani AK, Robertson D & Salser W. Overproduction of dihydrofolate reductase and gene amplification in methotrexate-resistant Chinese hamster ovary cells. Mol Cell Biol 1982;2:275-285.
30. Flintoff WF, Livingston E, Duff C & Worton RG. Moderate level gene amplification in methotrexate-resistant Chinese hamster ovary cells is accompanied by chromosomal translocations at or near the site of the amplified DHFR gene. Mol Cell Biol 1984;4:69-76.
31. Lewis JA, Biedler JL & Melera PW. Gene amplification accompanies low level increases in the activity of dihydrofolate reductase in antifolate-resistant Chinese hamster lung cells containing abnormally banding chromosomes. J Cell Biol 1982;94:418-424.
32. Mullner E, Hofbauer R & Wintersberger E. Increased levels of dihydrofolate reductase mRNA can be measured in normal, growth-stimulated mouse fibroblasts. Biochem Biophys Acta 1983;740:436-440.
33. Trent JM, Buick RN, Olson S, Horns RC Jr. & Schimke RT. Cytologic evidence for gene amplification in methotrexate-resistant cells obtained from a patient with ovarian adenocarcinoma. J Clin Oncol 1984;2:8-15.
34. Kaufman RJ, Brown PC & Schimke RT. Amplified dihydrofolate reductase genes in unstably methotrexate-resistant cells are associated with double minute chromosomes. Proc Natl Acad Sci USA 1979;76:5659-5673.
35. Schweitzer BI, Dicker AP & Bertino JR. Dihydrofolate reductase as a therapeutic target. FASEB J 1990;4:2441-2452.
36. Melera PW. Acquired versus intrinsic resistance to methotrexate: diversity of the drug-resistant phenotype in mammalian cells. Semin Cancer Biol 1991;2:245-255.
37. Dicker AP, Waltham MC, Volkenandt M, Schweitzer BI, Otter GM, Schmid FA et al. Methotrexate resistance in an in vivo mouse tumor due to a non-active-site dihydrofolate reductase mutation. Proc Natl Acad Sci USA 1993;11797-801.
38. Hanggi UJ & Littlefield JW. Isolation and characterization of the multiple forms of dihydrofolate reductase from methotrexate-resistant hamster cells. J Biol Chem 1974;249:1390-1397.
39. Flintoff WF & Essani K. Methotrexate-resistant Chinese hamster ovary cells contain a dihydrofolate reductase with an altered affinity for methotrexate. Biochemistry 1980;19:4321-4327.
40. Albrecht AM, Biedler JL & Hutchison DJ. Two different species of dihydrofolate reductase in mammalian cells differently resistant to amethropterin and methasquin. Cancer Res 1972;32:1539-1546.
41. Dedhar S & Goldie JF. Overproduction of two antigenically distinct forms of dihydrofolate reductase in a highly methotrexate-resistant mouse leukemia cell line. Cancer Res 1983;43:4863.
42. Duffy TH, Beckman SB & Huennekens FM. Multiple forms of L1210 dihydrofolate reductase differing in affinity for methotrexate. Biochem Biophys Res Commun 1984;119:352-358.
43. Haber DA, Beverley SM, Kiely ML & Schinmke RT. Properties of an altered dihydrofolate reductase encoded by amplified genes in cultured mouse fibroblasts. J Biol Chem 1981;256:9501-9510.
44. Melera PW, Lewis JA, Biedler JL & Hession C. Antifolate resistant Chinese hamster cells: evidence for dihydrofolate reductase gene amplification among independently derived sublines overproducing different dihydrofolate reductases. J Biol Chem 1980;255:7024-7028.
45. Iqbal MP & Rothenberg SP. A new form of dihydrofolate reductase in cancer cells. J Pak Med Assoc 1985;35:237-242.
46. Iqbal MP, Waqar MA, Mehboobali N & Malik I. A low affinity binder of methotrexate in human leukemia cells. Biochem Soc Trans 1990;18:633-634.
47. Iqbal MP, Rothenberg SP & da Costa M. Evidence for kinetic and immunologic heterogeneity of dihydrofolate reductase in L1210 leukemia cells. Biochem Med Metab Biol 1991;46:196-207.
48. Gurtoo HL, Hipkens JH & Sharma CD. Role of glutathione in the metabolism dependent toxicity and chemotherapy of cyclophosphamide. Cancer Res 1981;41:3584-3591.
49. Ozols RF, O' Dwyer PJ, Hamilton TC & Young RC. The role of glutathione in drug resistance. Cancer Treat Rev 1990;17:45-50.
50. Suzukake K, Vistica BP & Vistica DT. Dechlorination of L-phenylalanine mustard by sensitive and resistant tumor cells and its relationship to intracellular glutathione content. Biochem Pharmacol 1983;32: 165-167.
51. Arrick BA & Nathan CF. Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res 1984;44:4224-4232.
52. Meister A. Selective modification of glutathione metabolism. Science 1983;220:472-477.
53. Andrews PA, Murphy MP & Howell SB. Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion Cancer Res 1985;45:6250-6253.
54. Canada A, Herman L, Kidd K, Roberrson C & Trump D. Glutathione depletion increases the cytotoxicity of melphalan to PC-3 an androgen-insensitive prostate cancer cell line. Cancer Chemother Pharmacol 1993;32:73-77.
55. Green JA, Vistica DT, Young RC, Hamilton TC, Rogan AM & Ozols RF. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res 1984;44:5427-5431.
56. Hamilton TC, Winkler C, Louie K, Batist G, Bchrens B, Tsuruo T et al. Augmentation of adriamycin, melphalan and cisplatin cytotoxicity in drug-resistant and sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion Biochem Pharmacol 1985;34:2583-2586.
57. Suzukake K, Petro BJ & Vistica DT. Reduction in glutathione content of L-PAM-resistant L1210 cells confers drug sensitivity. Biochem Pharmacol 1982;31:121-124.
58. Louie KG, Behrens BC, Kinsella TJ, Hamilton TC, Grotzinger KR, McKoy WM et al. Radiation survival parameters of antineoplastic drug sensitive and resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res 1985;45:2110-2115.
59. Somfai-Relle S, Suzukake K, Vistica BP & Vistiea DT. Reduction in cellular glutathione by buthionine sulfoximine and sensitization of murine tumor cells resistant to L-phenylalanine mustard. Biochem Pharmacol 1984;33:485-490.
60. Ozols RF, Louie KG, Plowman J, Behrens BC, Fine RL, Dykes D et al. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochem Pharmacol 1987;36:147-153.
61. Lind MJ, McGowan AT, Hadfield JA, Thatcher N, Crowther D & Fox BW. The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo. Biochem Pharmacol 1989;38:1835-1840
62. Meier T, Allenbacher A, Mueller F, Multhoff G, Botzler C, Weisnet M et al. Ifosfamide induced depletion of glutathione in human peripheral blood lymphocytes and protection by mesna. Anticancer Drugs 1994;5:403-409.
63. Malik IA, Mehboobali N & Iqbal MP. Effect of ifosfamide on intracellular glutathione levels in peripheral blood lymphocytes and its correlation with therapeutic response in patients with advanced ovarian cancer. Cancer Chemother Pharmacol 1997;39:561-565.
64. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-810.
65. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994;78:539-42.
66. Spinella MJ, Brigle KE, Sierra EE & Goldman ID. Distinguishing between folate receptor-alpha-mediated transport and reduced folate carrier-mediated transport in L1210 leukemia cells. J Biol Chem 1995;270:7842-9.
67. Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D & Bertino JR. Intrinsic and acquired resistance to methotrexate in acute leukemia. Drug therapy 1996;335:1041-1048.
68. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB & Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994;54:2287-2291.
69. Reed JC. Bcl-2 prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 1995;9:451-473.
70. McFadyen, MC, McLeod HL, Jackson, FC, Melvin WT, Doehmer J. & Murray G.I. Cytochrome P450 CYP1B1 protein expressions: a novel mechanism of anticancer drug resistance. Biochem Pharmacol 2001;62:207-212.
71. Komatani H, Kotani H, Hara Y, Nakagawa R, Matsumoto M, Arakawa H et al. Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. Cancer Res 2001;61:2827-2832,
72. Lee JS, Scala S, Matsumoto Y, Dickstein B, Robey R, Zhan Z et al. Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated with P-glycoprotein or MRP expression. J Cell Biochem 1997;65:513-526.
73. Dwivedi RS, Wang LJ & Mirkin BL. S-adenosylmethionine synthetase is overexpressed in murine neuroblastoma cells resistant to nucleoside analogue inhibitors of S-adenosyl homocysteine hydrolase a novel mechanism of drug resistance. Cancer Res 1999;59:1852-1856.
74. Li W, Fan J, Hochhauser D, Banerjee D, Zielinski Z, Almasan A et al. Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc Natl Acad Sci USA 1995;92:10436-40.
75. Ahuja HG, Jat PS, Foti A, Bar-Eli M. & Cline MJ. Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia. Blood 1991;78:3259-3268.
76. Kornblau SM, Xu HJ, Zhang W, Hu SX, Beran M, Smith TL et al. Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia. Blood 1994;84:256-261.